Moreover, the 36-month beta value for TOI is 0.16. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TOI is 38.73M and currently, short sellers hold a 4.82% of that float. On June 04, 2025, TOI’s average trading volume was 1.26M shares.
TOI) stock’s latest price update
The stock of Oncology Institute Inc (NASDAQ: TOI) has decreased by -1.54 when compared to last closing price of 3.25. Despite this, the company has experienced a 6.31% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-03 that CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23.
TOI’s Market Performance
Oncology Institute Inc (TOI) has experienced a 6.31% rise in stock performance for the past week, with a 14.29% rise in the past month, and a 363.63% rise in the past quarter. The volatility ratio for the week is 2.06%, and the volatility levels for the past 30 days are at 7.88% for TOI. The simple moving average for the last 20 days is 9.99% for TOI stock, with a simple moving average of 248.61% for the last 200 days.
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with BTIG Research repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to BTIG Research is $7 based on the research report published on May 15, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see TOI reach a price target of $2.50. The rating they have provided for TOI stocks is “Buy” according to the report published on February 26th, 2024.
Guggenheim gave a rating of “Buy” to TOI, setting the target price at $7 in the report published on September 14th of the previous year.
TOI Trading at 36.44% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.57% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TOI starting from BRADFORD DANIEL HIVELY, who proposed sale 39,600 shares at the price of $2.87 back on Jun 03 ’25. After this action, BRADFORD DANIEL HIVELY now owns shares of Oncology Institute Inc, valued at $113,652 using the latest closing price.
BRADFORD DANIEL HIVELY, the Director of Oncology Institute Inc, proposed sale 1,936,537 shares at $2.87 during a trade that took place back on Jun 03 ’25, which means that BRADFORD DANIEL HIVELY is holding shares at $5,557,861 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -0.13 for the present operating margin
- 0.1 for the gross margin
The net margin for Oncology Institute Inc stands at -0.17. The total capital return value is set at -0.5. Equity return is now at value -227.77, with -28.66 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 0.85 points at debt to capital in total, while cash flow to debt ratio is standing at -0.55. The debt to equity ratio resting at 5.61. The interest coverage ratio of the stock is -4.7.
Currently, EBITDA for the company is -50.88 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 0.68. The receivables turnover for the company is 8.12for trailing twelve months and the total asset turnover is 2.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
To wrap up, the performance of Oncology Institute Inc (TOI) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
